The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease

Abstract From the Canadian patent

Disclosed are medicines for treating systemic lupus erythematosus and/or inflammatory bowel disease such as Crohn's disease or ulcerative colitis, which comprise a growth hormone secretagogue (GHS), prodrug thereof or a pharmaceutically acceptable salt of the GHS or the prodrug. More particularly the GHS is a compound of the Formula I: (see formula I), (in which HET is a heterocyclic moiety; R3 is alkyl etc.; R4 is, H, alkyl, etc.; X4 is H or alkyl; R6 is bond alkylene, etc.; R7, and R8 are each H, alkyl etc.) or a prodrug thereof or a, pharmaceutically acceptable salt of the GHS or the prodrug. Also disclosed are combinations of a GHS and a second therapeutic agent, where the second …